Evaluation of D-TACE Combined with Endovascular Brachytherapy for HCC with MPVTT

Overview

Journal Front Oncol

Specialty Oncology

Date 2022 Sep 5

PMID 36059634

Authors

Wei Huang

Ju Gong

Qingbing Wang

Ziyin Wang

Qin Liu

Jingjing Liu

Junwei Gu

Xiaoyi Ding

Zhiyuan Wu

Affiliations

Soon will be listed here.

Abstract

Background: Hepatocellular carcinoma (HCC) patients with main portal vein tumor thrombus (MPVTT) may be able to have TACE through stent implantation into the portal vein with thrombosis to recover portal blood flow.

Purpose: The goal of this study was to compare clinical results of conventional transcatheter arterial chemoembolization (C-TACE) and doxorubicin-eluting bead transcatheter arterial chemoembolization (D-TACE) combined with endovascular brachytherapy in HCC patients with MPVTT.

Methods: This study was a retrospective controlled study with follow-up dates spanning from Mar 2015 to Feb 2020. Patients with both HCC and MPVTT were divided into two groups. Portal vein stents with iodine-125 seed strands were implanted first; then, C-TACE or D-TACE was administered to all patients. Objective response rates were assessed.

Results: A total of 26 patients were enrolled, with 13 in each group. During follow-up, the portal stent patency times were 112.3 ± 98.2 days in the C-TACE group and 101.7 ± 90.4 days in the D-TACE group. The time to disease progression was 42 days in the C-TACE group and 120 days in the D-TACE group (p=0.03). The overall survival time from the first intervention procedure was 216 days in the C-TACE group and 239 days in the D-TACE group (p=0.047). The D-TACE group was superior to the C-TACE group in terms of progression-free survival (PFS) and overall survival (OS) times.

Conclusion: Endovascular implantation of brachytherapy combined with TACE is safe and effective in HCC patients with MPVTT. This combination therapy may be helpful for survival benefits to patients with stage BCLC-C HCC.

Citing Articles

Efficacy and safety of transcatheter arterial chemoembolization combined with sorafenib and sintilimab in the treatment of unresectable hepatocellular carcinoma.

Zhang J, Wei L, Tang H Am J Transl Res. 2025; 16(12):7849-7858.

PMID: 39822508 PMC: 11733392. DOI: 10.62347/KNIV1276.

References

Gomes A, Monteleone P, Sayre J, Finn R, Sadeghi S, Tong M . Comparison of Triple-Drug Transcatheter Arterial Chemoembolization (TACE) With Single-Drug TACE Using Doxorubicin-Eluting Beads: Long-Term Survival in 313 Patients. AJR Am J Roentgenol. 2017; 209(4):722-732. DOI: 10.2214/AJR.17.18219. View

Sidawy A, Weiswasser J, Waksman R . Peripheral vascular brachytherapy. J Vasc Surg. 2002; 35(5):1041-7. DOI: 10.1067/mva.2002.123751. View

Lu J, Zhang X, Zhong B, Lau W, Madoff D, Davidson J . Management of patients with hepatocellular carcinoma and portal vein tumour thrombosis: comparing east and west. Lancet Gastroenterol Hepatol. 2019; 4(9):721-730. DOI: 10.1016/S2468-1253(19)30178-5. View

Luo J, Yan Z, Liu Q, Qu X, Wang J . Endovascular placement of iodine-125 seed strand and stent combined with chemoembolization for treatment of hepatocellular carcinoma with tumor thrombus in main portal vein. J Vasc Interv Radiol. 2011; 22(4):479-89. DOI: 10.1016/j.jvir.2010.11.029. View

Wu Y, Wang T, Yue Z, Zhao H, Wang L, Fan Z . Stents combined with iodine-125 implantation to treat main portal vein tumor thrombus. World J Gastrointest Oncol. 2019; 10(12):496-504. PMC: 6304304. DOI: 10.4251/wjgo.v10.i12.496. View

Lencioni R, Llovet J . Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010; 30(1):52-60. DOI: 10.1055/s-0030-1247132. View

Lee H, Park S, Seo Y, Yoon W, Rim C, The Korean Liver Cancer Study Group . Benefits of Local Treatment Including External Radiotherapy for Hepatocellular Carcinoma with Portal Invasion. Biology (Basel). 2021; 10(4). PMC: 8070697. DOI: 10.3390/biology10040326. View

Zhang Y, Fan W, Wang Y, Lu L, Fu S, Yang J . Sorafenib With and Without Transarterial Chemoembolization for Advanced Hepatocellular Carcinoma With Main Portal Vein Tumor Thrombosis: A Retrospective Analysis. Oncologist. 2015; 20(12):1417-24. PMC: 4679083. DOI: 10.1634/theoncologist.2015-0196. View

Lu X, Dong J, Ji L, Luo J, Cao H, Xiao L . Safety and efficacy of TACE and gamma knife on hepatocellular carcinoma with portal vein invasion. Gut. 2015; 65(4):715-6. DOI: 10.1136/gutjnl-2015-310292. View

10.

Poon R, Tso W, Pang R, Ng K, Woo R, Tai K . A phase I/II trial of chemoembolization for hepatocellular carcinoma using a novel intra-arterial drug-eluting bead. Clin Gastroenterol Hepatol. 2007; 5(9):1100-8. DOI: 10.1016/j.cgh.2007.04.021. View

11.

Karalli A, Teiler J, Haji M, Seth E, Brismar T, Wahlin S . Comparison of lipiodol infusion and drug-eluting beads transarterial chemoembolization of hepatocellular carcinoma in a real-life setting. Scand J Gastroenterol. 2019; 54(7):905-912. DOI: 10.1080/00365521.2019.1632925. View

12.

Lammer J, Malagari K, Vogl T, Pilleul F, Denys A, Watkinson A . Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol. 2009; 33(1):41-52. PMC: 2816794. DOI: 10.1007/s00270-009-9711-7. View

13.

Brown K, Do R, Gonen M, Covey A, Getrajdman G, Sofocleous C . Randomized Trial of Hepatic Artery Embolization for Hepatocellular Carcinoma Using Doxorubicin-Eluting Microspheres Compared With Embolization With Microspheres Alone. J Clin Oncol. 2016; 34(17):2046-53. PMC: 4966514. DOI: 10.1200/JCO.2015.64.0821. View

14.

Zhang Z, Liu Q, Zhang W, Ma J, Wang J, Luo J . Combined endovascular brachytherapy, sorafenib, and transarterial chemobolization therapy for hepatocellular carcinoma patients with portal vein tumor thrombus. World J Gastroenterol. 2017; 23(43):7735-7745. PMC: 5703933. DOI: 10.3748/wjg.v23.i43.7735. View

15.

Rim C, Kim C, Yang D, Yoon W . Comparison of radiation therapy modalities for hepatocellular carcinoma with portal vein thrombosis: A meta-analysis and systematic review. Radiother Oncol. 2017; 129(1):112-122. DOI: 10.1016/j.radonc.2017.11.013. View

16.

Yang D, Park S, Rim C, Yoon W, Shin I, Lee H . Salvage External Beam Radiotherapy after Incomplete Transarterial Chemoembolization for Hepatocellular Carcinoma: A Meta-Analysis and Systematic Review. Medicina (Kaunas). 2021; 57(10). PMC: 8539441. DOI: 10.3390/medicina57101000. View

17.

Yoon S, Ryoo B, Lee S, Kim J, Shin J, An J . Efficacy and Safety of Transarterial Chemoembolization Plus External Beam Radiotherapy vs Sorafenib in Hepatocellular Carcinoma With Macroscopic Vascular Invasion: A Randomized Clinical Trial. JAMA Oncol. 2018; 4(5):661-669. PMC: 5885246. DOI: 10.1001/jamaoncol.2017.5847. View

18.

Long J, Zheng J, Sun B, Lu N . Microwave ablation of hepatocellular carcinoma with portal vein tumor thrombosis after transarterial chemoembolization: a prospective study. Hepatol Int. 2016; 10(1):175-84. DOI: 10.1007/s12072-015-9673-6. View

19.

Luo J, Zhang Z, Liu Q, Zhang W, Wang J, Yan Z . Endovascular brachytherapy combined with stent placement and TACE for treatment of HCC with main portal vein tumor thrombus. Hepatol Int. 2015; 10(1):185-95. DOI: 10.1007/s12072-015-9663-8. View

20.

Kang Y, Lee B, Kim J, Yim N, Kim H, Cho S . Conventional Versus Small Doxorubicin-eluting Bead Transcatheter Arterial Chemoembolization for Treating Barcelona Clinic Liver Cancer Stage 0/A Hepatocellular Carcinoma. Cardiovasc Intervent Radiol. 2019; 43(1):55-64. DOI: 10.1007/s00270-019-02349-9. View